-
Nanocytomics: Seeing tiny changes Nanocytomics LLC Evanston, Ill. Technology: Partial wave spectroscopic (PWS) microscope technology Disease focus: Diagnostic Clinical status: Pilot Founded: 2011 by Vadim …
Published on 2/6/2012
-
Nanocytomics thinks its high-resolution imaging technology can become standard of care to identify patients at high risk of developing some cancers before symptoms arise.
Published on 2/6/2012
-
Cantargia thinks its mAb targeting chronic myelogenous leukemia stem cells can provide the first curative therapy, which is not provided by chronic use of expensive TKIs.
Published on 1/30/2012
-
Cantargia: Stemming CML Cantargia AB Lund, Sweden Technology: mAbs targeting chronic myelogenous leukemia (CML) stem cells Disease focus: Cancer Clinical status: Lead optimization Founded: 2010 by Thoas Fioretos…
Published on 1/30/2012
-
RaNA is targeting long non-coding RNAs to up-regulate gene expression in a locus-specific fashion, which the company expects will provide specificity advantages over other epigenetic approaches.
Published on 1/23/2012
-
Founded by a management team with a track record of growing and selling dermatology companies, Dermira is starting with a targeted photodynamic therapy for acne.
Published on 1/23/2012
-
Dermira: Success is skin deep Dermira Inc. Redwood City, Calif. Technology: Topical photodynamic therapy and small molecules Disease focus: Dermatology Clinical status: Preclinical Founded: 2010 by Eugene Bauer,…
Published on 1/23/2012
-
RaNA: Specific in epigenetics RaNA Therapeutics Inc. Cambridge, Mass. Technology: Oligonucleotides targeted to long non-coding RNA (lncRNA) Disease focus: NA Clinical status: Preclinical Founded: 2011 by Atlas …
Published on 1/23/2012
-
NewGen: Compositions matter NewGen Therapeutics Inc. Menlo Park, Calif. Technology: Targeted small molecules for cancer Disease focus: Cancer Clinical status: Preclinical Founded: 2011 by Dennis Brown, Harry …
Published on 1/16/2012
-
NewGen is developing NCEs against validated cancer targets that it hopes can be best in class with strong IP positions. Its first three programs come from a Chinese biotech, Kanion Pharmaceutical.
Published on 1/16/2012
-
Rel-MD: Blocking two paths Rel-MD Inc. Baltimore, Md. Technology: Small molecule inhibitors of NF-kappa B proteins Disease focus: Cancer, autoimmune Clinical status: Preclinical Founded: 2011 by Jeffrey Meshulam…
Published on 1/16/2012
-
Rel-MD is betting on the lesser-known pathway for blocking NF-kB activation. The company has chosen multiple myeloma to show proof of principle with its REL inhibitors in tandem with Velcade.
Published on 1/16/2012
-
JDP is hoping its injectable non-sedative antihistamine can replace IV diphenhydramine as standard of care to treat acute allergic reactions, such as to food allergens, bee stings and drugs.
Published on 1/9/2012
-
JDP: Emergency antihistamines JDP Therapeutics Inc. Lansdale, Pa. Technology: Injectable formulation of an undisclosed marketed oral generic antihistamine Disease focus: Allergy and immunology Clinical status: …
Published on 1/9/2012
-
Anabasis is developing an ophthalmic formulation of nerve growth factor to provide disease-modifying treatment for neurotrophic keratitis, dry eye and glaucoma.
Published on 1/2/2012
-
Anabasis: Eyeing NGF Anabasis s.r.l. Milan, Italy Technology: Ophthalmic formulation of nerve growth factor (NGF) Disease focus: Ophthalmic Clinical status: Phase 0 Founded: 2009 by Luigi Aloe, Stefano Bonini, …
Published on 1/2/2012
-
Ultragenyx is taking a traditional approach to Orphan diseases by in-licensing substrate and enzyme replacement therapies that have a clear mechanistic rationale and animal data for genetic diseases.
Published on 12/19/2011
-
Ultragenyx: Back to Basics Ultragenyx Pharmaceutical Inc. Novato, Calif. Technology: NA Disease focus: Musculoskeletal, endocrine/metabolic Clinical status: Phase I Founded: 2010 by Emil Kakkis University …
Published on 12/19/2011
-
Sera Prognostics is developing a molecular test using nine biomarkers to more accurately predict women at risk for preterm birth, allowing earlier monitoring and preventive treatment.
Published on 12/12/2011
-
Sera Prognostics: Predicting preemies Sera Prognostics Inc. Salt Lake City, Utah Technology: Blood-based protein assay for preterm birth Disease focus: Diagnostic Clinical status: Validation Founded: 2008 by M. …
Published on 12/12/2011
-
Euthymics: Balancing act Euthymics Bioscience Inc. Cambridge, Mass. Technology: Selective triple monoamine reuptake inhibitors Disease focus: Neurology Clinical status: Phase IIb Founded: 2009 by Anthony …
Published on 12/5/2011
-
Euthymics thinks a molecule orphaned by Dov Pharma has the right balance of monoamine reuptake inhibition to offer better efficacy and fewer side effects than marketed drugs for major depressive disorder.
Published on 12/5/2011
-
Kareus is using its Karlect linker technology to generate new chemical entities by covalently linking two compounds for simultaneous dosing in a target tissue.
Published on 11/21/2011
-
Kareus: Linking up in AD Kareus Therapeutics S.A. La Chaux-de-Fonds, Switzerland Technology: Karlect drug linker technology Disease focus: Neurology, endocrine/metabolic, inflammation Clinical status: Preclinical…
Published on 11/21/2011
-
Aura: Protein particles deliver siRNA Aura Biosciences Inc. Cambridge, Mass. Technology: Nanosmart viral protein-based nanoparticles for tumor-specific delivery of therapeutics and imaging agents Disease focus: …
Published on 11/14/2011